PBAC Public Summary Documents - March 2011
Public summary documents relating to the March 2011 PBAC meeting
Page last updated: 21 July 2011
- Bevacizumab, solution for I.V. infusion, 100 mg in 4 mL and 400 mg in 16 mL, Avastin®, March 2011
- Bortezomib, powder for injection, 1 mg (solvent required), Velcade®, March 2011
- Capecitabine, tablet, 150 mg and 500 mg, Xeloda®, March 2011
- Cladribine, tablet, 10 mg, Movectro®, March 2011
- Colistimethate sodium, powder for nebuliser solution, 1 million IU (equivalent to 80 mg colistimethate sodium), Tadim®, March 2011
- Dabigatran etexilate, capsules, 110 mg and 150 mg (as mesilate), Pradaxa®, March 2011
- Eltrombopag, tablets, 25 mg and 50 mg, (as olamine), Revolade®, March 2011
- Fingolimod, capsule, 0.5 mg (as hydrochloride), Gilenya®, March 2011
- Imatinib, tablet, 100 mg and 400 mg (as mesylate), Glivec®, March 2011
- Lenalidomide, capsules, 5 mg and 10 mg, Revlimid®, March 2011
- Mannitol, capsule containing powder for oral inhalation, 40 mg (for use in inhaler device), Bronchitol®, March 2011
- Paricalcitol, capsule, 1 microgram and 2 micrograms, Zemplar®, March 2011
- Pregabalin, capsule, 25 mg, 75 mg, 150 mg and 300 mg, Lyrica®, March 2011
- Quadrivalent human papillomavirus (Types 6, 11, 16, 18) recombinant vaccine, suspension for injection, 0.5 mL, suspension for injection pre-filled syringe single dose, Gardasil®®, March 2011
- Risperidone, powder for I.M. injection, 25 mg, 37.5 mg and 50 mg (modified release) with 2 mL diluent in pre-filled syringe, Risperdal Consta®, March 2011
- Sertindole, tablet, 4 mg, 12 mg, 16 mg, 20 mg, Serdolect®, March 2011
- Tapentadol, tablet, 50 mg, 100 mg, 150 mg, 200 mg and 250 mg (as hydrochloride) (sustained release), Palexia SR®, March 2011
- Telmisartan with amlodipine, tablet, 40 mg – 5 mg, 40 mg – 10 mg, 80 mg – 5 mg and 80 mg – 10 mg (as besylate), Twynsta®, March 2011
- Tobramycin, solution for inhalation, single dose units, 300 mg in 5 mL, 56, TOBI,®, March 2011
- Vorinostat, capsule, 100 mg, Zolinza®, March 2011
